Hyperthermic Intraperitoneal Chemotherapy for Primary or Recurrent Adrenocortical Carcinoma. A Single Center Study.
adrenocortical carcinoma
hyperthermic intraperitoneal chemotherapy
safety
survival analysis
tumor recurrence
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Apr 2020
14 Apr 2020
Historique:
received:
25
02
2020
revised:
30
03
2020
accepted:
10
04
2020
entrez:
17
4
2020
pubmed:
17
4
2020
medline:
17
4
2020
Statut:
epublish
Résumé
This study explores the impact of Hypertermic Intra PEritoneal Chemotherapy (HIPEC) on adrenocortical carcinoma (ACC) management through a safety analysis completed by a preliminary evaluation of survival performances. Retrospective chart review of 27 patients submitted to surgical treatment completed by HIPEC for primary (SP, 13 patients) or recurrent (SR, 14 patients, 17 treatments) ACC. Safety was evaluated by means of procedural morbidity and mortality. Survival performances included multiple end points: local/peritoneal disease-free survival (l/pDFS), overall progression-free survival (OPFS), and overall survival (OS). In the SP group, mortality was nil and morbidity was 46% (major 23%). At a median follow-up of 25 months, the median value for all the different survival measures had not been reached. Mortality was also nil in the SR group. However, morbidity was 77% (major 18%). Median l/pDFS and OPFS were 12 ± 4 and 8 ± 2 months, respectively. At a median follow-up of 30 months, median OS had not been reached. Surgery and HIPEC is an invasive procedure. Its employment in the surgery for primary setting deserves attention as it may affect oncologic outcomes positively. Its value in the management of recurrences seems less appreciable, albeit it may find its place in the multimodal management of a rare disease for which multiple therapeutic options do not yet exist.
Sections du résumé
BACKGROUND
BACKGROUND
This study explores the impact of Hypertermic Intra PEritoneal Chemotherapy (HIPEC) on adrenocortical carcinoma (ACC) management through a safety analysis completed by a preliminary evaluation of survival performances.
METHODS
METHODS
Retrospective chart review of 27 patients submitted to surgical treatment completed by HIPEC for primary (SP, 13 patients) or recurrent (SR, 14 patients, 17 treatments) ACC. Safety was evaluated by means of procedural morbidity and mortality. Survival performances included multiple end points: local/peritoneal disease-free survival (l/pDFS), overall progression-free survival (OPFS), and overall survival (OS).
RESULTS
RESULTS
In the SP group, mortality was nil and morbidity was 46% (major 23%). At a median follow-up of 25 months, the median value for all the different survival measures had not been reached. Mortality was also nil in the SR group. However, morbidity was 77% (major 18%). Median l/pDFS and OPFS were 12 ± 4 and 8 ± 2 months, respectively. At a median follow-up of 30 months, median OS had not been reached.
CONCLUSION
CONCLUSIONS
Surgery and HIPEC is an invasive procedure. Its employment in the surgery for primary setting deserves attention as it may affect oncologic outcomes positively. Its value in the management of recurrences seems less appreciable, albeit it may find its place in the multimodal management of a rare disease for which multiple therapeutic options do not yet exist.
Identifiants
pubmed: 32295220
pii: cancers12040969
doi: 10.3390/cancers12040969
pmc: PMC7226100
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Surg Oncol. 2012 Jun 1;105(7):709-13
pubmed: 22189845
J Clin Endocrinol Metab. 2013 Jan;98(1):181-91
pubmed: 23150691
Cancer. 2008 Dec 1;113(11):3130-6
pubmed: 18973179
Ann Surg Oncol. 2012 Aug;19(8):2643-51
pubmed: 22526905
Surgery. 1997 Dec;122(6):1212-8
pubmed: 9426440
Ann Surg Oncol. 2019 Feb;26(2):531-538
pubmed: 30443830
Surgery. 2019 Jan;165(1):186-195
pubmed: 30343951
J Am Coll Surg. 2016 Dec;223(6):794-803
pubmed: 27618748
Onco Targets Ther. 2013 Jun 06;6:635-43
pubmed: 23776337
Surg Endosc. 2013 Nov;27(11):4026-32
pubmed: 23765427
Tumori. 2016 Dec 1;102(6):588-592
pubmed: 27716880
Cancer. 2010 Dec 15;116(24):5608-18
pubmed: 20737573
Ann Surg Oncol. 2013 Oct;20(11):3519-26
pubmed: 23748607
Ann Surg Oncol. 2008 Mar;15(3):754-63
pubmed: 18080166
J Surg Res. 2018 Dec;232:383-388
pubmed: 30463745
Cancer. 2009 Jan 15;115(2):243-50
pubmed: 19025987
Surgery. 2020 Feb;167(2):352-357
pubmed: 31272813
Eur J Endocrinol. 2018 Oct 01;179(4):G1-G46
pubmed: 30299884
Surgery. 2013 Dec;154(6):1292-9; discussion 1299
pubmed: 24238048
Ann Surg Oncol. 1999 Dec;6(8):719-26
pubmed: 10622498